These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2957983)

  • 21. Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis.
    Killian JM; Bressler RB; Armstrong RM; Huston DP
    Arch Neurol; 1988 Jan; 45(1):27-30. PubMed ID: 3276298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic progressive multiple sclerosis: changes in phenotype and function of T helper subsets.
    O'Gorman MR; Aziz T; Oger J
    J Neuroimmunol; 1989 Sep; 24(1-2):163-8. PubMed ID: 2530247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppressor-inducer T-cells in multiple sclerosis.
    Rose LM; Ledbetter JA; Ginsberg AH; Clark EA; Rothstein TL
    N Engl J Med; 1987 Jul; 317(2):118-9. PubMed ID: 2953974
    [No Abstract]   [Full Text] [Related]  

  • 24. Lymphocyte subpopulations in patients with multiple sclerosis.
    Compston A
    J Neurol Neurosurg Psychiatry; 1983 Feb; 46(2):105-14. PubMed ID: 6221079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphocyte subpopulations.
    Jenkins JS
    Diabet Med; 1987; 4(1):19-23. PubMed ID: 2951214
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunohistochemical analysis of suppressor-inducer and helper-inducer T cells in multiple sclerosis brain tissue.
    Sobel RA; Hafler DA; Castro EE; Morimoto C; Weiner HL
    Ann N Y Acad Sci; 1988; 540():306-8. PubMed ID: 2905121
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunologic effects of plasmapheresis synchronized with pulse cyclophosphamide in systemic lupus erythematosus.
    Dau PC; Callahan J; Parker R; Golbus J
    J Rheumatol; 1991 Feb; 18(2):270-6. PubMed ID: 1827161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppressor T-lymphocytes in multiple sclerosis: analysis of patients with acute relapsing and chronic progressive disease.
    Paty DW; Kastrukoff L; Morgan N; Hiob L
    Ann Neurol; 1983 Oct; 14(4):445-9. PubMed ID: 6227277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diurnal variation of lymphocyte subsets identified by monoclonal antibodies.
    Bertouch JV; Roberts-Thomson PJ; Bradley J
    Br Med J (Clin Res Ed); 1983 Apr; 286(6372):1171-2. PubMed ID: 6220755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.
    Berd D; Mastrangelo MJ
    Cancer Res; 1988 Mar; 48(6):1671-5. PubMed ID: 2830969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human T-cell growth factor (TCGF).
    Sarin PS; Gallo RC
    Crit Rev Immunol; 1984; 4(4):279-305. PubMed ID: 6232114
    [No Abstract]   [Full Text] [Related]  

  • 33. The presentation of cell surface alloantigens to T cells.
    Owens T; Czitrom AA; Gascoigne NR; Crispe IN; Ratcliffe MJ; Lai PK; Mitchison NA
    Immunobiology; 1984 Dec; 168(3-5):189-201. PubMed ID: 6241598
    [No Abstract]   [Full Text] [Related]  

  • 34. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
    Hauser SL; Dawson DM; Lehrich JR; Beal MF; Kevy SV; Propper RD; Mills JA; Weiner HL
    N Engl J Med; 1983 Jan; 308(4):173-80. PubMed ID: 6294517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Surface phenotypes of peripheral blood mononuclear cells in multiple sclerosis].
    Wender M; Sniatała-Kamasa M
    Neurol Neurochir Pol; 1988; 22(3):177-83. PubMed ID: 2975766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis.
    Hafler DA; Orav J; Gertz R; Stazzone L; Weiner HL
    J Neuroimmunol; 1991 May; 32(2):149-58. PubMed ID: 1672870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective loss of a subset of T helper cells in active multiple sclerosis.
    Rose LM; Ginsberg AH; Rothstein TL; Ledbetter JA; Clark EA
    Proc Natl Acad Sci U S A; 1985 Nov; 82(21):7389-93. PubMed ID: 2932738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss of functional suppression is linked to decreases in circulating suppressor-inducer (CD4+ 2H4+) T cells in multiple sclerosis.
    Chofflon M; Weiner HL; Hafler DA
    Ann N Y Acad Sci; 1988; 540():330-2. PubMed ID: 2905122
    [No Abstract]   [Full Text] [Related]  

  • 39. Abnormalities of immunocyte function in multiple sclerosis.
    Arnason BG
    Acta Neuropathol Suppl; 1983; 9():7-20. PubMed ID: 6226171
    [No Abstract]   [Full Text] [Related]  

  • 40. Magnetic resonance imaging in multiple sclerosis: analysis of correlations to peripheral blood and spinal fluid abnormalities.
    Farlow MR; Edwards MK; Kolar OJ; Stevens JC; Yu PL
    Neurology; 1987 Sep; 37(9):1527-30. PubMed ID: 2957612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.